ARIX BIOSCIENCE ORD 0.001P
ARIX BIOSCIENCE ORD 0.001P
Open: -
Change: -
Volume: -
Low: -
High: -
High / Low range: -
Type: Stocks
Ticker: ARIX
ISIN: GB00BD045071

Hardman & Co Research: Q&A with Q&A with Dr Dorothea Hill on Arix Bioscience (ARIX)

  • 45

Hardman & Co Research
Hardman & Co Research: Q&A with Q&A with Dr Dorothea Hill on Arix Bioscience (ARIX)

03-March-2020 / 07:30 GMT/BST


Hardman & Co Research: Q&A with Dr Dorothea Hill on Arix Bioscience

Arix Bioscience plc (ARIX) is the topic of discussion when Hardman & Co's analyst Dr Dorothea Hill caught up with DirectorsTalk for an exclusive interview.

Please click on the link below to listen to the interview:

https://vimeo.com/394373727

If you are interested in meeting the company, you can register your interest by clicking on the above link

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH

www.hardmanandco.com

Follow us on Twitter @HardmanandCo

Contact:

Dorothea Hill

+44 20 7194 7622

 

[email protected]
 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

 



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

987915  03-March-2020 

fncls.ssp?fn=show_t_gif&application_id=987915&application_name=news&site_id=centralchart
EQS Group
EQS Group

EQS Group is a leading international technology provider for Digital Investor Relations, Corporate Communications and Compliance. More than 8,000 companies worldwide trust EQS’s products and services to securely, efficiently, and simultaneously fulfil complex national and international disclosure and compliance requirements, and to reach stakeholders globally.